Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2014, and highlighted recent progress in advancing its pipeline.
“During the third quarter and recent period we continued advancing RNAi therapeutics through the clinic and toward the market. Notably, we reported six-month clinical data from our Phase 2 open-label extension study with patisiran, showing what we believe to be promising initial results.
Help employers find you! Check out all the jobs and post your resume.
“During the third quarter and recent period we continued advancing RNAi therapeutics through the clinic and toward the market. Notably, we reported six-month clinical data from our Phase 2 open-label extension study with patisiran, showing what we believe to be promising initial results.
Help employers find you! Check out all the jobs and post your resume.
